Doxazosin Modified release tablets

High blood pressure requires consistent, long-term management to reduce the risk of stroke, heart attack, and other serious cardiovascular events. Doxazosin modified release tablets are a once-daily prescription alpha-blocker used to treat hypertension in adults. The modified-release formulation delivers doxazosin gradually throughout the day, providing sustained blood pressure control and reducing the risk of the sharp early drop in blood pressure associated with standard-release alpha blocker tablets. Doxazosin modified release is also licensed for the treatment of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate gland. These tablets must be swallowed whole and must not be crushed or chewed. A prescription can only be issued following a clinical consultation with a registered prescriber.

Doxazosin modified release tablets are an oral prescription medicine containing doxazosin mesilate as the active ingredient. They belong to the alpha-1 adrenoceptor blocker class of medicines, commonly referred to as alpha blockers. Unlike the standard-release formulation of doxazosin, which releases the medicine rapidly and requires careful first-dose management, the modified-release formulation uses a controlled-release system (GITS: gastrointestinal therapeutic system) to deliver doxazosin at a consistent rate throughout the day as the tablet passes through the gastrointestinal tract.

Doxazosin modified release is licensed in the United Kingdom for two indications: the treatment of hypertension and the treatment of signs and symptoms of benign prostatic hyperplasia. It is available in two strengths: 4mg and 8mg tablets. The modified-release formulation is taken once daily and does not require the cautious first-dose titration at bedtime that is associated with standard-release doxazosin.

All clinical information on this page is drawn from the current UK Summary of Product Characteristics for doxazosin modified-release tablets.

Important: Doxazosin modified release tablets must be swallowed whole with a sufficient amount of liquid. Do not crush, break, or chew the tablet. The modified-release mechanism depends on the tablet remaining intact. Destroying the tablet releases the full dose rapidly, which can cause a significant fall in blood pressure.

Doxazosin works by selectively blocking alpha-1 adrenoceptors, which are found in the walls of blood vessels and in the smooth muscle of the prostate gland and bladder neck.

Effect on Blood Pressure

Alpha-1 adrenoceptors in blood vessel walls are normally stimulated by noradrenaline, which causes vasoconstriction (narrowing of blood vessels). By blocking these receptors, doxazosin causes vasodilation (widening of blood vessels), reducing peripheral vascular resistance and lowering blood pressure. The modified-release formulation provides a gradual, steady release of doxazosin, avoiding the peak blood levels associated with standard-release tablets. This reduces the risk of postural hypotension (a sudden fall in blood pressure on standing), which is more pronounced with standard-release alpha blockers.

Effect on Benign Prostatic Hyperplasia

In the prostate gland and bladder neck, alpha-1 adrenoceptors control the tone of the smooth muscle that surrounds the urethra. In BPH, an enlarged prostate causes this smooth muscle to contract, obstructing urine flow and causing symptoms such as difficulty starting urination, poor flow, frequent urination, and incomplete bladder emptying. By blocking alpha-1 receptors in the prostate and bladder neck, doxazosin relaxes this smooth muscle, relieving the obstruction and improving urinary symptoms.

Modified-Release Advantage

The GITS modified-release system maintains a more consistent plasma level of doxazosin throughout the day compared to standard-release tablets. This steady concentration supports consistent blood pressure control and reduces the peak-to-trough variation that can cause dizziness or postural hypotension. It also allows the starting dose of 4mg once daily to be used without the bedtime first-dose requirement of standard-release doxazosin.

Always take doxazosin modified release exactly as your prescriber instructs. The information below summarises key points from the current UK SmPC. Read the Patient Information Leaflet supplied with your medicine before starting treatment.

• Take doxazosin modified release once daily, at the same time each day, preferably in the morning with breakfast.
• Swallow the tablet whole with a sufficient amount of liquid. Do not crush, break, or chew the tablet. The modified-release mechanism relies on the tablet remaining intact throughout its passage through the gastrointestinal tract.
• Do not be alarmed if you notice a tablet-like shell in your stool. This is the empty outer casing of the GITS system after the medicine has been released and is a normal occurrence.
• If you miss a dose, take it as soon as you remember on the same day. If you only remember the following day, skip the missed dose and continue with your normal schedule. Do not take two doses on the same day.
• Do not stop taking doxazosin modified release without speaking to your prescriber first. Stopping suddenly may cause your blood pressure to rise.
• Take care when standing up, particularly in the first few days of treatment or after a dose increase. Rise slowly from a seated or lying position to reduce the risk of dizziness.

Doxazosin modified release tablets are available in two strengths through this service. The appropriate dose will be determined by your prescriber based on your blood pressure, urinary symptoms if applicable, and your response to treatment.

Doxazosin Modified Release 4mg Tablets

The 4mg tablet is the starting dose for most adults. For hypertension, treatment begins at 4mg once daily and the blood pressure response is assessed after one to two weeks. For BPH, 4mg once daily is also the starting dose. Many patients with hypertension achieve adequate blood pressure control on 4mg. The modified-release formulation does not require the gradual titration from 1mg associated with standard-release doxazosin and can be started directly at 4mg without a bedtime first dose.

Doxazosin Modified Release 8mg Tablets

If blood pressure or urinary symptoms remain inadequately controlled on 4mg, the dose may be increased to 8mg once daily after one to two weeks at the lower dose. The 8mg tablet is the maximum licensed dose for both hypertension and BPH in the modified-release formulation. All dose adjustments are made by your prescriber. Do not increase your dose without medical advice.

Like all medicines, doxazosin modified release can cause side effects, although not everyone experiences them. The information below is based on the current UK SmPC. Refer to the Patient Information Leaflet for the full list.

Common Side Effects (may affect up to 1 in 10 people)

• Dizziness or lightheadedness, particularly when standing up quickly (postural hypotension). This is most likely to occur in the first few days of treatment or after a dose increase.
• Headache.
• Fatigue and tiredness.
• Oedema (swelling of the ankles, feet, or legs).
• Palpitations (awareness of the heartbeat).
• Nausea or gastrointestinal discomfort.

Uncommon Side Effects (may affect up to 1 in 100 people)

• Low blood pressure (hypotension).
• Urinary incontinence, particularly in women.
• Dry mouth.
• Skin rash or itching.
• Sleep disturbance.

Serious Side Effects: Seek Urgent Medical Attention

Contact your prescriber or go to your nearest accident and emergency department promptly if you experience any of the following:

• Prolonged or painful erection (priapism) - this is a rare but serious side effect of alpha blockers that requires immediate medical attention. If not treated promptly, priapism can cause permanent damage.
• Severe dizziness or fainting, particularly when standing, which may indicate a significant fall in blood pressure.
• Signs of a serious allergic reaction, such as sudden swelling of the face, lips, tongue, or throat; difficulty breathing; or a severe skin reaction.
• Intraoperative floppy iris syndrome - if you are due to have cataract surgery or other eye surgery, inform your ophthalmologist that you are taking doxazosin. Alpha blockers can affect iris behaviour during eye surgery, even if treatment has been stopped. This must be disclosed before any ophthalmic procedure.

Report any suspected side effect to your prescriber or pharmacist or via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Doxazosin Modified Release Tablets May Be Suitable If You:

• Are an adult with hypertension who requires antihypertensive treatment, particularly as an adjunct to other antihypertensive medicines.
• Are an adult male with lower urinary tract symptoms associated with benign prostatic hyperplasia who requires treatment.
• Are already prescribed doxazosin modified release and require a repeat prescription through an online prescribing service.

Doxazosin Modified Release Tablets Are Not Suitable If You:

• Have a history of postural hypotension (low blood pressure on standing) or are at high risk of hypotension.
• Have severe liver impairment, as doxazosin is extensively metabolised in the liver and blood levels may be significantly raised.
• Are being treated for hypertension with monotherapy if you have had a history of heart failure or have a diagnosed history of orthostatic hypotension from another cause.
• Have a known allergy or hypersensitivity to doxazosin, other quinazoline derivatives (such as prazosin or terazosin), or any excipient listed in the SmPC.
• Are under 18 years of age (this service is for adults only).

Cautions

Particular care is required in patients with liver impairment, as doxazosin is highly metabolised by the liver. Patients with severe liver impairment should not take doxazosin. Older patients are at greater risk of postural hypotension and falls. Any patient taking doxazosin who is due to have eye surgery should inform their ophthalmologist well in advance, as intraoperative floppy iris syndrome can occur during cataract surgery in patients taking or who have previously taken alpha blockers, even if treatment has been discontinued. This risk persists after stopping the medicine.

Important Drug Interactions

Doxazosin can interact with a number of commonly prescribed medicines. Tell your prescriber about all medicines you take, including over-the-counter products and supplements. The following interactions are of particular clinical importance:

• Other antihypertensive medicines: the blood pressure-lowering effect of doxazosin may be significantly enhanced when combined with other medicines that reduce blood pressure, including calcium channel blockers, ACE inhibitors, ARBs, beta blockers, and diuretics.
• PDE-5 inhibitors (such as sildenafil, tadalafil, and vardenafil): combining alpha blockers with PDE-5 inhibitors can cause a significant and potentially dangerous fall in blood pressure. If you take both medicines, your prescriber will advise on timing and doses to minimise this risk.
• NSAIDs such as ibuprofen: these can reduce the antihypertensive effect of doxazosin.
• Alpha blockers used for BPH (such as tamsulosin, alfuzosin): combining doxazosin with another alpha blocker increases the risk of hypotension significantly.

This is not a complete list of interactions. Your prescriber will carry out a full clinical assessment, including a review of your current medicines, before any prescription is considered.

Doxazosin modified release is a prescription-only medicine. The clinical consultation is the essential first step. A prescription will only be issued if a registered prescriber determines, based on their individual assessment of your circumstances, that doxazosin modified release is clinically appropriate for you.

During your online consultation with Pharmacy Planet, a registered prescriber will review your clinical information. This includes your blood pressure readings, relevant medical history, current medicines, and any urinary symptoms if BPH is the indication. The prescriber will also assess whether the modified-release formulation is the most appropriate form of doxazosin for your circumstances.

Not all consultations will result in a prescription being issued. The prescriber may recommend a different dose or a different medicine or suggest that a face-to-face appointment with your GP or urologist is more appropriate. This process is designed to ensure your safety.

If you are already being managed for hypertension or BPH by your GP or a specialist, please keep them informed of all medicines you are taking, including any prescribed through online services.

• Store below 30°C.
• Store in the original packaging to protect from light and moisture.
• Keep out of the sight and reach of children.
• Do not use after the expiry date printed on the packaging.
• Do not dispose of medicines via household waste or wastewater. Return unused or out-of-date tablets to your pharmacist for safe disposal.

Full storage instructions are provided in the Patient Information Leaflet supplied with your medicine.

The table below compares the two doxazosin formulations available at Pharmacy Planet. Both are alpha-1 adrenoceptor blockers used for high blood pressure and, in men, for symptoms of benign prostatic hyperplasia.

Important: This comparison is for general information only and does not replace medical advice. A prescriber will decide which treatment is suitable for you following an online consultation.

Pharmacy Planet is a GPhC-registered online pharmacy providing access to prescription medicines through a clinically led consultation process. Our registered prescribers and pharmacists are committed to patient safety, clinical accuracy, and responsible prescribing.

We follow GPhC standards, MHRA guidance, and ASA advertising regulations in all aspects of our service. Every prescription is reviewed and dispensed by qualified healthcare professionals. We provide clear, factual information to help patients understand their antihypertensive medication and make informed decisions about their health.

If you have questions about doxazosin modified release, alpha blocker therapy, or cardiovascular or urological health, our pharmacy team is available to help. We are committed to transparent, patient-centred care.

References

1. Electronic Medicines Compendium (eMC). Doxazosin Modified Release 4mg and 8mg Tablets — Summary of Product Characteristics. https://www.medicines.org.uk/emc. Accessed August 2026.
2. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline NG136. https://www.nice.org.uk/guidance/ng136. Accessed August 2026.
3. NHS. Doxazosin. https://www.nhs.uk/medicines/doxazosin. Accessed August 2026.
4. Joint Formulary Committee. British National Formulary (BNF). Doxazosin. BMJ Group and Pharmaceutical Press. https://bnf.nice.org.uk. Accessed August 2026.
5. Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card — report a side effect. https://yellowcard.mhra.gov.uk. Accessed August 2026.